Operating cash flow decreased 9.3%
Operating cash flow changed -9.3% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
$185.3M→$168.1M3 prior comparisons
GROSSPATTERN / DETERMINISTIC EVIDENCE / V3
Search securities →BMRN financial changes
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Capital expenditure increased 68.5%
Capital expenditure changed +68.5% from the comparable as-filed period.
$17.1M→$28.8M3 prior comparisons
Free-cash-flow margin moved 630 bp lower
Free-cash-flow margin changed -630 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
20.37%→14.07%2 prior comparisons
Operating cash-flow margin moved 546 bp lower
Operating cash-flow margin changed -546 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
22.45%→16.99%2 prior comparisons
Operating cash flow / net income increased 387.6%
Operating cash flow / net income changed +387.6% from the comparable as-filed period.
0.77→3.762 prior comparisons
SBC / revenue moved 189 bp higher
SBC / revenue changed +189 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
5.76%→7.65%2 prior comparisons
Receivables / revenue moved 352 bp higher
Receivables / revenue changed +352 basis points from the comparable as-filed period.
103.69%→107.21%2 prior comparisons
Current ratio decreased 57.1%
Current ratio changed -57.1% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
5.56→2.394 prior comparisons
Capex / revenue moved 84 bp higher
Capex / revenue changed +84 basis points from the comparable as-filed period.
2.07%→2.91%2 prior comparisons
Current assets increased 4.4%
Current assets changed +4.4% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
$3.8B→$4.0B4 prior comparisons
Shares outstanding increased 0.8%
Shares outstanding changed +0.8% from the comparable as-filed period. The change ranks at the 38th percentile of 8 prior comparable changes.
192,014,601→193,573,7598 prior comparisons
R&D / revenue moved 137 bp higher
R&D / revenue changed +137 basis points from the comparable as-filed period.
19.54%→20.91%2 prior comparisons
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.